Large scale therapeutic production requires careful monitoring of protein aggregates
Scientists must efficiently produce recombinant proteins, such as monoclonal antibodies, on a large scale for biotherapeutics development. Many chemical and physical factors compromise protein stability and lead to protein unfolding and aggregation. Luckily, there are several methods for detecting and eliminating protein aggregates.
Download this ebook from Enzo to learn about
Current FDA regulations for therapeutic protein products
Techniques for determining the stability of protein-based pharmaceuticals
